Navigation Links
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
Date:2/13/2009

less than 6.0 mg/dL at the final visit (both p<0.001).

ULORIC has an established safety profile with no dose adjustments required in patients with mild-to-moderate renal or hepatic impairment. The most commonly reported adverse reactions were liver function abnormalities, nausea, joint pain and rash.

"We are pleased to offer a new treatment option, the first in 40 years, to the more than five million Americans who have hyperuricemia associated with gout, fulfilling an unmet need," said Alan MacKenzie, president and CEO, Takeda Pharmaceuticals North America, Inc. "At Takeda, we are deeply committed to developing strong clinical programs and bringing to market innovative therapies, like ULORIC, for patients. This approval is a significant milestone for Takeda, as it marks our second approval within a month."

About Gout and Hyperuricemia

Uric acid is an end-product created when the body breaks down substances called purines. Hyperuricemia occurs when this process results in elevated uric acid levels, either through overproduction or underexcretion of uric acid or a combination of the two. Hyperuricemia is a precursor to gout; the higher a person's urate level, the greater the risk for developing gout.

Gout is the most common inflammatory arthritis in men over age 40. According to the National Health and Nutrition Examination Survey III 1988-1994, an estimated 5.1 million Americans suffer from gout. It is a chronic condition characterized by attacks, or "flares," marked by intense pain, redness, swelling and heat in the affected joint.

These symptoms are the result of an acute inflammatory response to the presence of crystallized uric acid in the joint(s). As the disease progresses, gout symptoms may become more frequent and patients may develop large deposits of crystallized uric acid visible under the skin, known as tophi.

About ULORIC (febuxo
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
2. FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
3. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
4. Monsanto Board Approves 10 Percent Dividend Increase
5. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
6. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
7. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
8. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
9. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
10. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
11. FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2
... magnetic fields and tiny iron-bearing particles to drive healthy ... done in animals, may lead to a new method ... diseased organs in people. , The study team, led ... Chair of Pediatric Cardiology at The Childrens Hospital of ...
... BALTIMORE, Jan. 7 Physicians and ... California will benefit from,a new partnership ... University,Medical Center, providing resources to help ... thereby improving patient care., (Logo: ...
... 7 Cephalon, Inc. (Nasdaq:,CEPH) announced today that the ... the JPMorgan Healthcare Conference are now available on the,"Investor ... On Tuesday, January 8, 2008, Frank Baldino, Jr.,Ph.D., Chairman ... the,Conference beginning at 2:00 p.m. Pacific Time (5 p.m. ...
Cached Biology Technology:Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California 2Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... and the Quebec government have discovered microplastics (in ... of Fisheries and Aquatic Sciences . , The ... industrial cleansers, to which they are commonly added ... buoyancy, they may readily pass through sewage treatment ... the world,s oceans, but have only recently been ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... have fish-like sensations, advanced ship design and more, four ... on Dec. 23 learned they will receive the nation,s ... researchers have been selected for Presidential Early Career Awards ... at a ceremony at the White House early this ...
... forces in a quest to correct a faulty chromosome through ... , used stem cells to correct a defective "ring chromosome" ... correct chromosome abnormalities that give rise to birth defects, mental ... may be possible to use this approach to take cells ...
... a key difference in the biological mechanisms by which the ... study, published in the journal Nature Immunology and ... Life Sciences, centred on STAT1, a protein that can bind ... in the body. STAT-1 responds to interferon signals, hormone-like ...
Cached Biology News:White House lauds ONR-funded researchers for early success 2Nature study discovers chromosome therapy to correct a severe chromosome defect 2Nature study discovers chromosome therapy to correct a severe chromosome defect 3Research uncovers key difference between our bodies' fight against viruses and bacteria 2
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... Antibody against Nonmuscle Myosin II Heavy ... (Stored in TBS + 0.03% Thimerosal) ... peptide SDVNETQPPQSE corresponding to the C-terminus ... B (MHC-B) This antibody is effective ...
... Anti-Mi-2 Immunogen : ... acid residues 474-970 of human ... 7.4, 0.105M NaCl, 0.035% sodium ... Assurance: routinely evaluated by immunoblot ...
Biology Products: